

<p align="center">U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p align="center">INFORMATION DISCLOSURE CITATION</p> <p align="center"><i>(Use several sheets if necessary)</i></p> <p align="right">Page 1 of 1</p>	<p>ATTY. DOCKET NO. MGH-028AUS</p>	<p>APPLICATION NO. 10/814,852</p>
	<p>APPLICANT Maurizio Fava et al.</p>	
	<p>FILING DATE March 31, 2004</p>	<p>GROUP 3626</p>

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)		
		Klein et al.; "Improving Clinical Trials" American Society of Clinical Psychopharmacology Recommendations, Arch Gen Psychiatry/Vol. 59, March 2002, pp. 272-278.
		Doody et al.; "Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer Disease", Arch Neurol/Vol. 58, March 2001, pp. 427-433.
		Grandi; "The Sequential Parallel Comparison Model: A Revolution in the Design of Clinical Trials", Affective Disorders Program, Department of Psychology, University of Bologna, Bologna, Italy, Psychotherapy and Psychosomatics 2003; 72:113-114.
		Laughren; "The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective", Eur Psychiatry 2001; 16: 418-23.
		Holbrook et al.; "Innovation and placebos in research: a new design of clinical trial", The Lancet, Vol. 362, December 20/27, 2003, pp. 2036-2037.
		Koch et al.; "A Two-Period Crossover Design For The Comparison Of Two Active Treatments And Placebo", Statistics In Medicine, Vol. 8, 487-504 (1989).
		Noseworthy et al.; "The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial" American Academy of Neurology, 1994; 44:16-18.
		Streiner; "Placebo-controlled trials: when are they needed?" Schizophrenia Research 35 (1999), 201-210.
		Talbot; "The Placebo Prescription", <i>New York Times Magazine</i> , January 9, 2000, 10 pages.
		Hrobjartsson et al.; "Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment", Journal of Internal Medicine 2004; 256:91-100.
		Hart; "The mysterious placebo effect", Modern Drug Discovery, July/August 1999, 2 (4) 30-40, 7 pages.
		Faraone et al.; "The Drug-Placebo Response Curve: A New Method for Assessing Drug Effects in Clinical Trials", Journal of Clinical Psychopharmacology: December 2000 – Volume 20 – Issue 6 – pp. 673-679.
		Nordenberg; "The Healing Power of Placebos", The Body, <i>FDA Consumer</i> , January/February 2000, 6 pages.
		Zelen; "A New Design For Randomized Clinical Trials", The New England Journal of Medicine, Vol. 300, No. 22, May 31, 1979, pp. 1242-1245.
		Hrobjartsson et al; "Is the Placebo Powerless? An Analysis of Clinical Trials Comparing Placebo with No Treatment", The New England Journal of Medicine, Vol. 344, No. 21, May 24, 2001, pp. 1594-1603
		Ellenberg; "Randomization Designs In Comparative Clinical Trials", The New England Journal of Medicine, Vol. 310, No. 21, May 24, 1984, 1404-1408.
		Beller et al.; "Randomisation in clinical trials", MJA, Vol. 177, November 18, 2002, 565-567.
		Altman et al.; "Statistics notes How to randomize", BMJ, Volume 319, September 11, 1999, 703-704.
Examiner		Date Considered:
		*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.